Cibc Asset Management Inc Arrowhead Pharmaceuticals, Inc. Transaction History

Cibc Asset Management Inc

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 09, 2022	SELL	$27.79 - $50.61 $122,748 - $223,544	-4,417 Closed	0 $0
Q4 2021 Feb 08, 2022	BUY	$58.09 - $82.51 $13,128 - $18,647	226 Added 5.39%	4,417 $293,000
Q3 2021 Nov 09, 2021	BUY	$58.38 - $84.96 $22,301 - $32,454	382 Added 10.03%	4,191 $262,000
Q1 2021 May 14, 2021	BUY	$61.35 - $90.47 $11,104 - $16,375	181 Added 4.99%	3,809 $253,000
Q4 2020 Feb 03, 2021	BUY	$43.82 - $85.37 $158,978 - $309,722	3,628 New	3,628 $278,000
Q1 2020 Apr 30, 2020	SELL	$20.56 - $63.12 $72,741 - $223,318	-3,538 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$28.14 - $73.01 $99,559 - $258,309	3,538 New	3,538 $224,000

294

90.8M

155K

426K

Ticker ARWR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 105,849,000
Market Cap $2.01B
Description
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, w...

Get notified when there are updates to the investment portfolio of Cibc Asset Management Inc, based on Form 13F filings with the SEC.

Stay updated on Cibc Asset Management Inc with notifications on news.